New immunotherapy trial targets Hard-to-Treat prostate cancer
Disease control
Recruiting now
This study tests a new treatment called SYNC-T therapy (SV-102) for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The goal is to find the safest and most effective dose and see if it can shrink tumors. About 91 me…
Phase: PHASE2 • Sponsor: Syncromune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC